인간 마이크로바이옴 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global human microbiome market size is expected to reach USD 5.78 Billion in 2034 from USD 1.51 Billion in 2025, growing at a CAGR of 16.08% during 2026-2034.The global human microbiome market is experiencing rapid growth due to increasing research on the role of microorganisms in human health. The human microbiome is linked to various conditions, including gastrointestinal disorders, metabolic diseases, and immune system regulation. Growing awareness about the importance of gut health and the rising demand for probiotic and microbiome-based therapies are driving market expansion. Additionally, advancements in sequencing technologies are enabling deeper insights into microbial communities.

Key growth drivers include increasing investments in microbiome research and the expanding applications of microbiome-based products in healthcare and nutrition. Pharmaceutical and biotechnology companies are focusing on developing microbiome-targeted therapies for various diseases. The rising popularity of personalized medicine and preventive healthcare is also contributing to market growth. Furthermore, collaborations between research institutions and industry players are accelerating innovation in this field.

Looking ahead, the human microbiome market is expected to grow significantly with ongoing research and technological advancements. The development of targeted microbiome therapies and diagnostics will expand clinical applications. Emerging markets are likely to offer new opportunities due to increasing health awareness and improving healthcare infrastructure. Additionally, regulatory advancements and standardization will support the commercialization of microbiome-based products.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Site

• Digestive Tract
• Lung
• Reproductive Cavity
• Skin
• Other Sites

By Application

• Therapeutics
• Diagnostics

By Disease

• Infectious Disease
• Gastrointestinal Disease
• Endocrine And Metabolic Diseases
• Cancer
• Central Nervous System Disorder
• Other Diseases

By Product

• Drugs
• Supplements
• Diagnostic Tests
• Other Products

COMPANIES PROFILED

• Archer Daniels Midland Company, Biohm Technologies, BioGaia, Biome Diagnostics, BiomeBank, Ferring, Intralytix, OptiBiotix, Pendulum Therapeutics, Prescient Metabiomics, Seres Therapeutics.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN MICROBIOME MARKET: BY SITE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Site
• 4.2. Digestive Tract Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Reproductive Cavity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Skin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Sites Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN MICROBIOME MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN MICROBIOME MARKET: BY DISEASE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease
• 6.2. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gastrointestinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Endocrine And Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Central Nervous System Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN MICROBIOME MARKET: BY PRODUCT 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Product
• 7.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HUMAN MICROBIOME MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Site
  • 8.2.2 By Application
  • 8.2.3 By Disease
  • 8.2.4 By Product
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Site
  • 8.3.2 By Application
  • 8.3.3 By Disease
  • 8.3.4 By Product
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Site
  • 8.4.2 By Application
  • 8.4.3 By Disease
  • 8.4.4 By Product
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Site
  • 8.5.2 By Application
  • 8.5.3 By Disease
  • 8.5.4 By Product
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Site
  • 8.6.2 By Application
  • 8.6.3 By Disease
  • 8.6.4 By Product
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL HUMAN MICROBIOME INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Biohm Technologies
  • 10.2.2 BioGaia
  • 10.2.3 Biome Diagnostics
  • 10.2.4 BiomeBank
  • 10.2.5 Ferring
  • 10.2.6 Intralytix
  • 10.2.7 OptiBiotix
  • 10.2.8 Pendulum Therapeutics
  • 10.2.9 Prescient Metabiomics
  • 10.2.10 Seres Therapeutics